{"sample":{"about":"An excerpt of the free IDeate-Lung01 report as the Erudio MCP library serves it without a key. Values are real; arrays are cut to one finding, two of its claims, their passages, sources and speakers. Lists of claim IDs inside the excerpt are cut to the claims shown.","full_report":"https://mcp.erudio.com/library/erudio-nct05280470/served.json","report_id":"erudio-nct05280470","counts_in_full_report":{"aspects":12,"evidence_units":284,"findings":8,"people":71,"sources":166,"verified_claims":369},"identifiers_with_the_identity_add_on":{"status":"included","details":"complete","erudio_id":"<Erudio profile ID>","npi":"<10-digit NPI>","x":{"author_id":"<X author ID>","username":"<X username>","url":"https://x.com/<X username>"},"links":[{"platform":"bluesky","url":"https://bsky.app/profile/<did>"},{"platform":"linkedin","url":"https://www.linkedin.com/in/<handle>"},{"platform":"institutional_profile","url":"https://<institution page>"}],"research_identifiers":[{"type":"orcid","identifier":"<ORCID iD>","url":"https://orcid.org/<ORCID iD>"},{"type":"openalex_author","identifier":"<OpenAlex author ID>","url":"https://openalex.org/<OpenAlex author ID>"}],"research_affiliations":[{"organization_name":"<institution>","ror_id":"https://ror.org/<ROR ID>","active_years":[2024,2025],"confirmation":"unconfirmed"}],"source":"NPI from the NPPES registry; X, Bluesky, LinkedIn and web pages verified by Erudio's identity checks; ORCID, OpenAlex and ROR from verified scholarly identity. Research affiliations come from publication records and are unconfirmed."}},"accounts":[{"id":"bluesky-author:did:plc:b6or56vkmhywvtt2wkcsnbsc","name":"OncLive"},{"id":"bluesky-author:did:plc:bxzk4m7k4l4pqhhbb3guu3qx","name":"Addario Lung Cancer Medical Institute (ALCMI)","source_names":["Addario Lung Cancer Medical Institute"]}],"analysis":"## Response activity and approval sufficiency are different judgments\n\nIn the sources reviewed for this edition, enthusiasm for I-DXd activity coexists with a separate question: was the evidence sufficient to support accelerated approval in the available-treatment landscape? Posts dated September 25, 2026 reported the voluntary application withdrawal. Shields described positive responses and brisk response timing, attributed concern about approval on Phase 2 findings alone to the company, and remained hopeful about future Phase 3 results. Her clinical concern was the scarcity of options for relapsed SCLC after tarlatamab, particularly alongside the reported loss of second-line lurbinectedin. Horinouchi emphasized that accelerated-approval requirements had not been satisfied. [claim-a0bb21ab8eb12174338a][claim-a58ca5972f579e92099a][claim-6dda39f8efb94e890472][claim-a54f13bcc639f1fdc78c]\n\nThis should not be converted into either a finding of no activity or a definitive explanation of FDA's reasoning. An unidentified account explicitly said the evidentiary shortcomings had not been publicly detailed and distinguished withdrawal from program abandonment. Another interpreted the setback as an earlier-stage data-sufficiency problem rather than evidence of treatment failure or a safety problem; that was the account's interpretation, not proof excluding a safety contribution. [claim-448660edb48aed0fac43][claim-0f14378eb8fff24cc9aa]\n\nA further unidentified account argued that tarlatamab's confirmed benefit had raised the meaningful-advantage standard. It expressly acknowledged that ILD deaths or the broader evidence package could have mattered as much. The same account argued that uncontrolled overall survival could accommodate either benefit or no benefit, warning against comparisons across regions and treatment lines and against generalizing the small second-line subgroup to the full cohort. [claim-378060ceae6cf518dc27][claim-378060ceae6cf518dc27-1b11eaeb]\n\nThe timing matters. Liu's September 13, 2026 comment that I-DXd might soon be available preceded the withdrawal reports. Later posts corrected the obsolete October 10 decision framing; they did not establish that a future filing or approval was assured. [claim-72588011f515294ed33b][claim-b0de7161cc64ee2ff379][claim-1b145a44397ce24b7cfa] Shields had anticipated an October review completion, while Ben Creelan regarded the news as abrupt and emphasized how difficult SCLC approval can be. Neither statement identifies the agency's detailed objection. [claim-8f019f39c96133b5c8b2][claim-06a9ea52af0db6789a8a]\n\nThe evidence-generation response was consistent with earlier interest in larger randomized studies: Alessandro Russo wanted such data, Hann described IDeate-Lung02 as the larger second-line comparison after one prior platinum line, and Socinski described its physician's-choice chemotherapy options, including amrubicin in Japan. Rudin expressed anticipation for the readout rather than certainty about its result. [claim-97096792f8bc446db119-94608858][claim-10417bd42bac0742210e][claim-1aa4433437a7b38d3c8d][claim-7af189aba17157fdaca4] Publisher reporting of insufficiency for accelerated approval provides context, not an additional HCP opinion. [claim-e25696e733db131375f2]\n","aspects":[{"claim_ids":["claim-dc5690d8cc42b039ea7e"],"context":"","context_claim_ids":[],"coverage":"discussed","id":"A3","limitations":["Frequent expression and biological rationale do not establish a predictive biomarker.","Hann's surprise at reported EGFR–HER3 ADC activity reflects her prior target-expression assumptions, not a demonstrated expression–response relationship. The reported 48% response rate is not a head-to-head comparison with I-DXd, and the agent's name is uncertain in the transcript.","The reported null expression–response association does not establish irrelevance to every selection question.","Similar-looking clinical data and China-only randomized results do not establish interchangeable global benefit–risk profiles."],"title":"B7-H3 biology, selection biomarkers and ADC differentiation"}],"claim_ids":["claim-a0bb21ab8eb12174338a","claim-dc5690d8cc42b039ea7e"],"cms_financial_relationships":{"caveat":"CMS-reported financial relationships come from CMS Open Payments, publication of 2026-06-30. The data covers US physicians, physician assistants and nurse practitioners only, and each program year is published about six months after it ends. Research amounts are institutional or study amounts, not personal compensation; ownership is reported separately. A company includes the CMS reporting entities it owned at the end of each program year; otherwise it is the entity CMS records as the submitter. Tags state a tie Erudio found in the trial's records; a company without one shows no tie found by Erudio. A payment can name several products. A record does not show why a clinician holds a view, and a missing record does not show that no financial relationship exists.","contract":"open-payments-cards-3","grouping_rule":"families-then-cms-submitter-1","label":"CMS-reported financial relationships","match_rule":"exact-name-core-2-families","no_tag_text":"no tie found by Erudio","publication":{"program_years":{"first":2019,"last":2025},"publication_id":1,"published":"2026-06-30"},"status_counts":{"no_npi":49,"no_records":0,"not_covered_recipient":1,"records":22},"tag_lookup_unmapped":[{"name":"Ifinatamab Deruxtecan (I-DXd)","reason":"no CMS-reported product with this name","relationship":"manufacturer"}],"tagged_companies":[{"canonical_organization_id":"daiichi-sankyo","cms_reporting_entities":[{"id":"100000000056","name":"Daiichi Sankyo Company LTD"},{"id":"100000000195","name":"Daiichi Sankyo Inc."},{"id":"100000081372","name":"Daiichi Sankyo Europe GmbH"}],"corporate_family":true,"name":"Daiichi Sankyo","tags":[{"basis":"registry_name","registry_name":"Daiichi Sankyo","source":"ClinicalTrials.gov registry","tag":"trial_sponsor"},{"basis":"cms_research_record_names_trial","cms_reporting_entity":"Daiichi Sankyo Inc.","source":"CMS Open Payments research records","tag":"funded_research_naming_this_trial"}]},{"canonical_organization_id":"merck-sharp-dohme","cms_reporting_entities":[{"id":"100000000053","name":"Merck Sharp & Dohme LLC"},{"id":"100000000055","name":"COMSORT, Inc"}],"corporate_family":true,"name":"Merck & Co. (MSD)","tags":[{"basis":"registry_name","registry_name":"Merck Sharp & Dohme LLC","source":"ClinicalTrials.gov registry","tag":"trial_collaborator"}]}]},"commentary_scope":{"basis":"The sources reviewed for this edition only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"retrieval_gaps":["Discussion that does not name the trial may be missing from this edition.","For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","271 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing."],"source_count":163,"unreadable_unit_ids":[]},"coverage":{"acquisition_gaps":["Discussion that does not name the trial may be missing from this edition."],"gaps":[],"sources":[{"assessed_characters":27056,"original_characters":27080,"reason":"","source_id":"clinicaltrials:NCT05280470:methods","status":"assessed","unreadable_characters":0}],"summary":{"fully_assessed_sources":166,"original_sources":166,"sources_with_unreadable_portions":0,"substantive_regions_with_relevant_material":812,"substantive_regions_without_relevant_commentary":440,"unreadable_regions":0}},"evidence_units":[{"attributed_person_id":"erudio:2709","context_ids":[],"end":1602,"evidence_role":"commentary","id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f@0:1602","kind":"turn","link":"https://x.com/i/status/2103626401861517784","source_id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f","start":0},{"attributed_person_id":"erudio:1062","context_ids":[],"end":306,"evidence_role":"commentary","id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa@0:306","kind":"turn","link":"https://x.com/i/status/2104906915553915013","source_id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa","start":0}],"executive_summary":"Among named clinicians in the sources reviewed for this edition, I-DXd generated optimism about treatment activity, while the reported accelerated-approval application withdrawal sharpened a different question: whether the evidence demonstrated sufficient benefit in an evolving treatment landscape. Shields remained hopeful about Phase 3 data but concerned about options after tarlatamab; Horinouchi reported that accelerated-approval requirements had not been satisfied. Neither account establishes no activity or termination of development. [claim-a0bb21ab8eb12174338a][claim-a58ca5972f579e92099a][claim-6dda39f8efb94e890472][claim-448660edb48aed0fac43]","findings":[{"actions":["How should scientific exchange distinguish response activity, comparative clinical benefit and accelerated-approval sufficiency?","Which conclusions about the withdrawal remain interpretations rather than an articulated FDA rationale?"],"claim_ids":["claim-a0bb21ab8eb12174338a","claim-dc5690d8cc42b039ea7e"],"counterviews":["An unidentified account interpreted the setback as data insufficiency rather than drug failure or a demonstrated safety problem; another argued that proven tarlatamab benefit had raised the comparison standard, while explicitly acknowledging that safety or other shortcomings could have mattered as much. [claim-0f14378eb8fff24cc9aa][claim-378060ceae6cf518dc27]","Fred R. Hirsch regarded the I-DXd news unfavorably but maintained strong confidence in B7-H3, citing other studies in the same setting. [claim-dc5690d8cc42b039ea7e]"],"id":"F1","interpretation":"The consequential distinction is between an encouraging treatment signal and evidence sufficient to establish benefit against an evolving treatment landscape. The detailed reason for FDA's assessment remains unresolved in the commentary. [claim-448660edb48aed0fac43][claim-378060ceae6cf518dc27]","limitations":["Accounts of FDA discussions are reported explanations, not a detailed agency assessment.","Earlier expectations of imminent availability describe their own dates; they should not be read as current access assurances."],"observation":"Misty Dawn Shields reported the application withdrawal while remaining hopeful about Phase 3 I-DXd data and concerned about options after tarlatamab. Hidehito Horinouchi reported that IDeate-Lung01 data did not satisfy accelerated-approval requirements. These statements do not establish that I-DXd lacked activity or that its development had ended. [claim-a0bb21ab8eb12174338a][claim-a58ca5972f579e92099a][claim-6dda39f8efb94e890472][claim-a54f13bcc639f1fdc78c]","title":"Response enthusiasm and evidence sufficient for accelerated approval are different judgments"}],"hcp_context_basis":"owner_curated_corpus","limitations":["The sources reviewed for this edition do not represent all HCP discussion or establish the prevalence of any opinion.","The material includes organizations, unidentified speakers and authors whose clinical roles are not established. Their statements are distinguished from identified clinician views."],"navigation":{"analysis":[{"id":"section-1","level":2,"title":"Response activity and approval sufficiency are different judgments"}],"executive_summary":[]},"out_of_scope_statements":{"count":270,"note":"Statements an automated screen judged to be about other treatment settings or topics outside this trial's question. They are not counted, priced or used in the findings; they are listed with links so a reader can check the screen's calls.","statements":[{"claim_id":"claim-11ec5e07d9fe16075204","link":"https://x.com/i/status/1665069760227287042","source_id":"mcp:x_thread:1665069760227287042:7fbc8bd2-2051-449a-a8ae-2436258d8360","source_title":"Advancing ADCs in SCLC: Key Insights from #ASCO23 on Precision Oncology","statement":"Nagla Abdel Karim said predictive biomarkers for ADCs in SCLC still need improvement."}]},"people":[{"claim_count":5,"cms_financial_relationships":{"companies":[{"cms_reporting_entities":[{"general_payment_count":32,"general_total_usd":"21858.36","id":"100000005637","name":"JAZZ PHARMACEUTICALS INC.","ownership_reported":false,"research_record_count":0}],"company":"JAZZ PHARMACEUTICALS INC.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"16290.00","nature":"Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program","payment_count":7},{"amount_usd":"2388.10","nature":"Travel and Lodging","payment_count":3},{"amount_usd":"1920.26","nature":"Food and Beverage","payment_count":21},{"amount_usd":"1260.00","nature":"Other","payment_count":1}],"payment_count":32,"total_usd":"21858.36"},"grouping":{"basis":"cms_submitting_entity","id":"jazzpharmaceuticalsinc"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"21858.36","name":"ZEPZELCA","record_count":32,"share":1}],"other":null,"top":[{"amount_usd":"21858.36","name":"ZEPZELCA","record_count":32,"share":1}]},"program_years":{"first":2022,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":9,"general_total_usd":"11988.43","id":"100000000146","name":"AstraZeneca Pharmaceuticals LP","ownership_reported":false,"research_record_count":0},{"general_payment_count":2,"general_total_usd":"4020.00","id":"100000010370","name":"AstraZeneca UK Limited","ownership_reported":false,"research_record_count":0}],"company":"AstraZeneca","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"14672.50","nature":"Consulting Fee","payment_count":6},{"amount_usd":"958.96","nature":"Travel and Lodging","payment_count":1},{"amount_usd":"376.97","nature":"Food and Beverage","payment_count":4}],"payment_count":11,"total_usd":"16008.43"},"grouping":{"basis":"corporate_family","id":"astrazeneca"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"11101.43","name":"IMFINZI","record_count":7,"share":1}],"other":null,"top":[{"amount_usd":"11101.43","name":"IMFINZI","record_count":7,"share":1}]},"program_years":{"first":2023,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":3,"general_total_usd":"478.73","id":"100000801827","name":"Pharmacosmos Therapeutics Inc.","ownership_reported":false,"research_record_count":0}],"company":"Pharmacosmos Therapeutics Inc.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"478.73","nature":"Food and Beverage","payment_count":3}],"payment_count":3,"total_usd":"478.73"},"grouping":{"basis":"cms_submitting_entity","id":"pharmacosmostherapeuticsinc"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"478.73","name":"COSELA","record_count":3,"share":1}],"other":null,"top":[{"amount_usd":"478.73","name":"COSELA","record_count":3,"share":1}]},"program_years":{"first":2024,"last":2024},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":5,"general_total_usd":"429.74","id":"100000000226","name":"Genentech USA, Inc.","ownership_reported":false,"research_record_count":0},{"general_payment_count":1,"general_total_usd":"38.48","id":"100000000089","name":"Genentech, Inc.","ownership_reported":false,"research_record_count":0}],"company":"Roche","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"468.22","nature":"Food and Beverage","payment_count":6}],"payment_count":6,"total_usd":"468.22"},"grouping":{"basis":"corporate_family","id":"roche"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"219.33","name":"Tecentriq","record_count":3,"share":0.4063},{"amount_usd":"133.04","name":"Alecensa","record_count":3,"share":0.2464},{"amount_usd":"110.53","name":"Rozlytrek","record_count":2,"share":0.2047},{"amount_usd":"38.48","name":"Avastin","record_count":1,"share":0.0713},{"amount_usd":"38.48","name":"Gavreto","record_count":1,"share":0.0713}],"other":{"amount_usd":"76.96","product_count":2,"record_count":2},"top":[{"amount_usd":"219.33","name":"Tecentriq","record_count":3,"share":0.4063},{"amount_usd":"133.04","name":"Alecensa","record_count":3,"share":0.2464},{"amount_usd":"110.53","name":"Rozlytrek","record_count":2,"share":0.2047}]},"program_years":{"first":2023,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"143.33","id":"100000000106","name":"Medtronic, Inc.","ownership_reported":false,"research_record_count":0}],"company":"Medtronic, Inc.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"143.33","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"143.33"},"grouping":{"basis":"cms_submitting_entity","id":"medtronicinc"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"143.33","name":"SIGNIA","record_count":1,"share":1}],"other":null,"top":[{"amount_usd":"143.33","name":"SIGNIA","record_count":1,"share":1}]},"program_years":{"first":2024,"last":2024},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"99.95","id":"100000000279","name":"Seagen Inc.","ownership_reported":false,"research_record_count":0}],"company":"Pfizer Inc.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"99.95","nature":"Education","payment_count":1}],"payment_count":1,"total_usd":"99.95"},"grouping":{"basis":"cms_submitting_entity","id":"pfizerinc"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2022,"last":2022},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"56.79","id":"100000481813","name":"CATALYST PHARMACEUTICALS, INC.","ownership_reported":false,"research_record_count":0}],"company":"CATALYST PHARMACEUTICALS, INC.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"56.79","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"56.79"},"grouping":{"basis":"cms_submitting_entity","id":"catalystpharmaceuticalsinc"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2024,"last":2024},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"49.75","id":"100000000195","name":"Daiichi Sankyo Inc.","ownership_reported":false,"research_record_count":0}],"company":"Daiichi Sankyo","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"49.75","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"49.75"},"grouping":{"basis":"corporate_family","id":"daiichi-sankyo"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"49.75","name":"Enhertu","record_count":1,"share":1}],"other":null,"top":[{"amount_usd":"49.75","name":"Enhertu","record_count":1,"share":1}]},"program_years":{"first":2025,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":null,"tags":[{"basis":"registry_name","registry_name":"Daiichi Sankyo","source":"ClinicalTrials.gov registry","tag":"trial_sponsor"},{"basis":"cms_research_record_names_trial","cms_reporting_entity":"Daiichi Sankyo Inc.","source":"CMS Open Payments research records","tag":"funded_research_naming_this_trial"}]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"24.46","id":"100000916825","name":"G1 Therapeutics, Inc.","ownership_reported":false,"research_record_count":0}],"company":"G1 Therapeutics, Inc.","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"24.46","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"24.46"},"grouping":{"basis":"cms_submitting_entity","id":"g1therapeuticsinc"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"24.46","name":"COSELA","record_count":1,"share":1}],"other":null,"top":[{"amount_usd":"24.46","name":"COSELA","record_count":1,"share":1}]},"program_years":{"first":2023,"last":2023},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"23.88","id":"100000000069","name":"Regeneron Pharmaceuticals, Inc.","ownership_reported":false,"research_record_count":0}],"company":"Regeneron","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"23.88","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"23.88"},"grouping":{"basis":"corporate_family","id":"regeneron"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"23.88","name":"LIBTAYO","record_count":1,"share":1}],"other":null,"top":[{"amount_usd":"23.88","name":"LIBTAYO","record_count":1,"share":1}]},"program_years":{"first":2023,"last":2023},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"23.43","id":"100000005499","name":"E.R. Squibb & Sons, L.L.C.","ownership_reported":false,"research_record_count":0}],"company":"Bristol Myers Squibb","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"23.43","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"23.43"},"grouping":{"basis":"corporate_family","id":"bristol-myers-squibb"},"ownership":{"reported":false},"products_named":{"all":[{"amount_usd":"23.43","name":"OPDIVO","record_count":1,"share":1}],"other":null,"top":[{"amount_usd":"23.43","name":"OPDIVO","record_count":1,"share":1}]},"program_years":{"first":2023,"last":2023},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"21.18","id":"100000000203","name":"Amgen Inc.","ownership_reported":false,"research_record_count":1}],"company":"Amgen","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"21.18","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"21.18"},"grouping":{"basis":"corporate_family","id":"amgen"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2023,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":true,"record_count":1},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":1,"general_total_usd":"20.36","id":"100000000329","name":"Janssen Biotech, Inc.","ownership_reported":false,"research_record_count":0}],"company":"Johnson & Johnson","general_payments":{"disputed_record_count":0,"natures":[{"amount_usd":"20.36","nature":"Food and Beverage","payment_count":1}],"payment_count":1,"total_usd":"20.36"},"grouping":{"basis":"corporate_family","id":"johnson-johnson"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2023,"last":2023},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":false,"record_count":0},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":0,"general_total_usd":"0.00","id":"100000000234","name":"Boehringer Ingelheim Pharmaceuticals, Inc.","ownership_reported":false,"research_record_count":9},{"general_payment_count":0,"general_total_usd":"0.00","id":"100000005541","name":"Boehringer Ingelheim International GmbH","ownership_reported":false,"research_record_count":1},{"general_payment_count":0,"general_total_usd":"0.00","id":"100000010823","name":"Boehringer Ingelheim Pharma GmbH & Co.KG","ownership_reported":false,"research_record_count":2}],"company":"Boehringer Ingelheim","general_payments":{"disputed_record_count":0,"natures":[],"payment_count":0,"total_usd":"0.00"},"grouping":{"basis":"corporate_family","id":"boehringer-ingelheim"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2023,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":true,"record_count":12},"tag_text":"no tie found by Erudio","tags":[]},{"cms_reporting_entities":[{"general_payment_count":0,"general_total_usd":"0.00","id":"100000191750","name":"PUMA BIOTECHNOLOGY, INC.","ownership_reported":false,"research_record_count":1}],"company":"PUMA BIOTECHNOLOGY, INC.","general_payments":{"disputed_record_count":0,"natures":[],"payment_count":0,"total_usd":"0.00"},"grouping":{"basis":"cms_submitting_entity","id":"pumabiotechnologyinc"},"ownership":{"reported":false},"products_named":{"all":[],"other":null,"top":[]},"program_years":{"first":2025,"last":2025},"research":{"amount_basis":"institutional or study amounts, not personal compensation","associated":true,"record_count":1},"tag_text":"no tie found by Erudio","tags":[]}],"company_count":15,"general_payment_count":61,"general_total_usd":"39276.87","status":"records","status_text":"CMS reported records for this NPI.","tagged_company_count":1},"id":"erudio:2709","name":"Misty Dawn Shields","qualification":"physician; Medical oncology; United States","role":"physician","specialty":"Medical oncology","identifiers":{"status":"not_included"}},{"claim_count":1,"cms_financial_relationships":{"status":"no_npi","status_text":"No verified NPI link, so CMS records are not looked up."},"id":"erudio:1062","name":"Fred R. Hirsch","qualification":"physician; Medical oncology; United States","role":"physician","specialty":"Medical oncology","identifiers":{"status":"not_verified"}}],"product_contract":"hcp-commentary-1","quotation":{"contract":"buyer-quotation-1","projection_of":"sha256:a3e66a4c8bc71219d025351edc9a2291eff4d2999ebd54176c0b9a670ee773a4","quote_words":25,"rule":"Claims are in Erudio's words. Each evidence reference shows at most one short excerpt with a link to the original; excerpts per source are limited, and source text is not redistributed.","source_quote_share":0.02,"source_quote_words":300},"schema_version":"5.2","source_context_unit_ids":["mcp:bluesky_thread:plc-bxzk4m7k4l4pqhhbb3guu3qx-3lxcolidp3g2d@269:813"],"sources":[{"content_hash":"9d7a2aba4b1dbac1b4ba4d8f4a40660e1d207a68309d84fd572548cd01cf8eaf","evidence_role":"commentary","id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f","kind":"commentary","metadata":{"author_display_names":"{\"x-author-id:1245179401265917955\":\"Ben Creelan, MD MS\",\"x-author-id:1859413411\":\"Misty Dawn Shields\"}","authors":"{\"x-author-id:1245179401265917955\":\"1245179401265917955\",\"x-author-id:1859413411\":\"1859413411\"}","conversation_id":"2103626401861517784","post_newest":"2026-09-26T12:56:55.000Z","post_oldest":"2026-09-25T23:23:12.000Z","total_posts":"2"},"retrieved_at":"2026-10-21T06:34:38.476042+00:00","title":"X thread, 2026-09-25","upstream_id":"x_thread:2103626401861517784","url":"https://x.com/i/status/2103626401861517784"},{"content_hash":"6fb4d376c9f30229539f30095c71f6f49bab1f7c331e30fa934d5db071718350","evidence_role":"commentary","id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa","kind":"commentary","metadata":{"author_display_names":"{\"x-author-id:2827663376\":\"Fred R. Hirsch\"}","authors":"{\"x-author-id:2827663376\":\"2827663376\"}","conversation_id":"2104906915553915013","post_newest":"2026-09-29T12:11:30.000Z","post_oldest":"2026-09-29T12:11:30.000Z","total_posts":"1"},"retrieved_at":"2026-10-21T06:34:39.305125+00:00","title":"X thread, 2026-09-29","upstream_id":"x_thread:2104906915553915013","url":"https://x.com/i/status/2104906915553915013"}],"statement_counts":{"counted":347,"listed":369,"restatements":22,"rule":"Each verified statement is counted once; a statement marked restatement_of repeats the statement it names from the same passage and is listed but not counted."},"title":"IDeate-Lung01: HCP interpretations of response activity, pulmonary risk and the post-tarlatamab treatment decision","trial":{"context":"{\"conditions\":[\"Extensive-stage Small-cell Lung Cancer\"],\"interventions\":[\"Ifinatamab Deruxtecan (I-DXd)\"],\"phases\":[\"PHASE2\"],\"primary_outcomes\":[\"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Following Treatment With I-DXd in Participants With Pretreated ES-SCLC\"]}","id":"NCT05280470","registry_url":"https://clinicaltrials.gov/study/NCT05280470","title":"A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)"},"trial_id":"NCT05280470","verified_claims":[{"evidence":[{"end":770,"link":"https://x.com/i/status/2103626401861517784","quote":"the company Merck (along with the Rx developer Daichii Sankyo) has WITHDRAWN their application from the FDA for accelerated approval today. The company expressed concerns …","role":"support","start":400,"unit_id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f@0:1602"}],"expression_type":"interpretation","id":"claim-a0bb21ab8eb12174338a","kind":"interpretation","person_id":"erudio:2709","qualifiers":["The concern about approval on Phase 2 findings alone is Shields's account of the company's concern.","The Phase 2 findings and response characteristics are stated as Shields described them.","She said the Phase 3 study was nearing completion."],"rationale":"Shields described the company's concern as she understood it and placed it alongside the Phase 2 findings and ongoing Phase 3 study.","speaker_binding":{"basis":"source_author","display_name":"Misty Dawn Shields","identifying_unit_id":"mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f@0:1602","speech_unit_ids":["mcp:x_thread:2103626401861517784:e722a98e-f8ae-4463-953e-e4754d15b48f@0:1602"]},"speech_ownership":"reported","statement":"Misty Dawn Shields said the company had expressed concern that I-DXd might not have been approved on Phase 2 findings alone. She noted that IDeate-Lung01 had positive findings with a high number of responses and brisk response time, while Phase 3 IDeate-Lung02 was nearing completion."},{"evidence":[{"end":306,"link":"https://x.com/i/status/2104906915553915013","quote":"so good news with I-Dxd in patients with SCLC! However, two large studies with B7-H3 antagonists in the same setting were very strongly positive presented …","role":"support","start":27,"unit_id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa@0:306"}],"expression_type":"comparison","id":"claim-dc5690d8cc42b039ea7e","kind":"attributed_opinion","person_id":"erudio:1062","qualifiers":["The characterization of TAISHAN and ARTEMIS as very strongly positive is Hirsch's statement.","His optimism is about the B7-H3 target in the same SCLC setting."],"rationale":"He contrasted the I-DXd news with his view of other B7-H3 studies in the same SCLC setting and maintained optimism about the target.","speaker_binding":{"basis":"source_author","display_name":"Fred R. Hirsch","identifying_unit_id":"mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa@0:306","speech_unit_ids":["mcp:x_thread:2104906915553915013:89e26ecf-3681-43d6-9205-8ef499ffe9fa@0:306"]},"speech_ownership":"direct","statement":"Fred R. Hirsch considered the I-DXd news unfavorable but said two large B7-H3 antagonist studies in the same setting, TAISHAN and ARTEMIS, had been very strongly positive at WCLC 2026. He remained a strong believer in the promise of the target."}],"identity_links":"Erudio holds identity linkages (NPI and other verified IDs) for the people in this report; this license does not include them. Each person card's identifiers.status says whether Erudio verified that person (not_included) or not (not_verified). Identity linkages come with the identity add-on on a 12-month weekly-updates plan, and a license can move to that plan by paying the difference: call create_order with product updates-12-identities and this license key, see https://www.erudio.com/pricing, or write to hello@erudio.com. Person cards here keep name, role, specialty, qualification and CMS-reported financial relationships."}